On Wednesday, Bank Of The Ozarks Inc (NASDAQ:OZRK)’s shares inclined 0.66% to $46.05.
Bank of the Ozarks, Inc. (OZRK) declared its Board of Directors has approved a regular quarterly cash dividend of $0.14 per common share payable July 24, 2015 to shareholders of record as of July 17, 2015. The dividend of $0.14 per common share represents an enhance of $0.005 per common share, or 3.7%, over the dividend paid in the previous quarter. The Company has raised its quarterly cash dividend in each of the last twenty quarters.
Bank of the Ozarks, Inc. is a bank holding company with $8.3 billion in total assets as of March 31, 2015 and trades on the NASDAQ Global Select Market under the symbol “OZRK.” The Company owns a state-chartered partner bank that conducts banking operations through 165 offices in Arkansas, Georgia, Texas, North Carolina, Florida, Alabama, South Carolina, New York and California. The Company may be contacted at (501) 978-2265 or P. O. Box 8811, Little Rock, Arkansas 72231-8811. The Company’s website is: www.bankozarks.com. \
Bank of the Ozarks, Inc. operates as the bank holding company for Bank of the Ozarks that provides a range of retail and commercial banking services. The company accepts various deposits products, such as checking, savings, money market, time deposit, and individual retirement accounts. Its loan portfolio comprises real estate loans, which comprise loans secured by residential 1-4 family, non-farm/non-residential, agricultural, construction/land development, multifamily residential properties, and other land loans; and consumer loans for purchasing automobiles, recreational vehicles, boats, and mobile homes. The company’s loan portfolio also comprise loans for commercial, industrial, and professional purposes, such as loans to fund working capital requirements, purchase of machinery and equipment, and other purposes, in addition to term loans, balloon loans, and lines of credit; and agricultural loans for financing agricultural production comprising of loans to businesses or individuals engaged in the production of timber, poultry, livestock, or crops.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s shares dropped -1.35% to $2.20.
Synta Pharmaceuticals Corp. (SNTA) declared the publication in this month’s issue of Cancer Immunology Research of an in-depth review describing the rationale for pursuing the combination of Hsp90 and immune checkpoint inhibition for cancer therapy. The review article, titled “Targeting Heat-Shock Protein 90 (Hsp90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy,” is accessible online at http://cancerimmunolres.aacrjournals.org. Synta is presently studying the Hsp90 inhibitor ganetespib in several randomized studies, counting the GALAXY-2 trial, a global, randomized, multi-center Phase 3 study of ganetespib and docetaxel for the second-line treatment of advanced non-small cell lung adenocarcinoma.
The review article describes preclinical findings that suggest that proteasomal degradation of cellular client proteins associated with Hsp90 inhibition may augment antitumor immune response through raised cellular antigen expression and subsequent improved T-cell recruitment and tumor-cell recognition. The review article also explains that client proteins affected by Hsp90 inhibition comprise oncogenes that may drive expression of Programmed Death-Ligand 1 (PD-L1), a key immune checkpoint. The resulting reduction of PD-L1 expression on tumor cells may enhance T-cell mediated cytotoxic activity and complement the activity of selective anti-PD-1 or anti-PD-L1 antibody therapies. This is supported by in vivo study results, where ganetespib was found to potentiate the antitumor efficacy of anti-PD-L1 antibody treatment. In these studies, the combination of ganetespib and an anti-PD-L1 antibody displayed significantly greater antitumor activity than either individual agent, in mouse models of both colon carcinoma and melanoma.
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate comprises ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
At the end of Wednesday’s trade, Radius Health Inc (NASDAQ:RDUS)‘s shares dipped -1.12% to $66.94.
Radius Health, Inc. (RDUS) reports top line data from the first six months of ACTIVExtend and the 25 month combined data from ACTIVE and ACTIVExtend. Additionally, Radius is reporting new data from an exploratory analysis of major osteoporotic fractures in the ACTIVE trial.
Radius formerly stated positive results in December 2014 for the Phase 3 ACTIVE Trial — meeting the primary endpoint of new vertebral fracture reduction (-86%, p < 0.0001) and secondary endpoints of non-vertebral fracture reduction (-43%, p = 0.0489) and BMD enhances at Spine (18M, 9.20% p < 0.0001), Femoral Neck (18M 2.90% p < 0.0001) and Total Hip (18M 3.44% p < 0.0001).
ACTIVExtend results show that the group formerly treated with abaloparatide had no new vertebral fractures during the first six months on alendronate. From the start of the ACTIVE study, this group showed an 87% reduction in new vertebral fractures (p < 0.0001), 52% reduction in non-vertebral fractures (p = 0.0168), 48% reduction in clinical fractures (p = 0.0139), and a 58% reduction in major osteoporotic fractures (p = 0.0122) over the 25-month period. A recent exploratory analysis of the ACTIVE trial showed that, for major osteoporotic fractures, there was a 67% reduction in major osteoporotic fractures (p = 0.0014) for the abaloparatide treatment group as compared to placebo, and a 53% reduction in major osteoporotic fractures (p = 0.0437) for the abaloparatide treatment group as contrast to teriparatide.
Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has accomplished Phase II clinical trial, which is used to enhance bone mineral density.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH), ended its Wednesday’s trading session with -1.16% loss, and closed at $8.52.
Anthera Pharmaceuticals Inc (ANTH) declared that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial evaluating blisibimod for the treatment of lupus. Final data from the trial is predictable in the second half of 2016.
Results from CHABLIS-SC1, and eventually CHABLIS-SC2, are anticipated to support marketing approval for blisibimod as a treatment for active SLE that is not controlled by current best practice standard-of-care, counting corticosteroids.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others. The company is also developing a Phase III product candidate Liprotamase, a non-porcine investigational pancreatic enzyme replacement therapy intended for the treatment of patients with exocrine pancreatic insufficiency. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
